Richard Peterson - Novan CFO
| NOVNDelisted Stock | USD 0.03 0.01 33.46% |
CFO
Mr. Richard D. Peterson is a Chief Financial Officer of the Company. He has served as our Chief Financial Officer since September 2015. Prior to joining Novan, Mr. Peterson was the Chief Financial Officer of Medicis Pharmaceutical Corporation from 2008 to 2012 and from 1995 to 2012, he served as Senior Vice President. He currently serves as a member of the board of directors of Universal Insurance Holdings, Incorporated. since 2015.
| Age | 47 |
| Tenure | 9 years |
| Phone | 919 485 8080 |
| Web | https://www.novan.com |
Novan Management Efficiency
The company has return on total asset (ROA) of (0.2584) % which means that it has lost $0.2584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9889) %, meaning that it created substantial loss on money invested by shareholders. Novan's management efficiency ratios could be used to measure how well Novan manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.93 M in liabilities with Debt to Equity (D/E) ratio of 4.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novan Inc has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Novan until it has trouble settling it off, either with new capital or with free cash flow. So, Novan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novan Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novan to invest in growth at high rates of return. When we think about Novan's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | CFO Age | ||
| Mario Paradis | Acasti Pharma | N/A | |
| Giuliano Fratta | Aeterna Zentaris | N/A | |
| James Mullaney | Ibio Inc | 46 | |
| Jeffrey Whitnell | Aeterna Zentaris | 57 | |
| Andrew CPA | Plus Therapeutics | 51 | |
| Stephen Tulipano | Aldeyra | 54 | |
| Joshua Reed | Aldeyra | 44 | |
| Patricia Bitar | TRACON Pharmaceuticals | 57 | |
| Jeffrey Farrow | Tarsus PharmaceuticalsInc | 62 | |
| M Morris | Tonix Pharmaceuticals Holding | N/A | |
| Bradley CPA | Tonix Pharmaceuticals Holding | 50 | |
| Jessica Morris | Tonix Pharmaceuticals Holding | 40 | |
| James Clavijo | Aeterna Zentaris | 51 | |
| Mark Giannone | Ibio Inc | 57 | |
| Karen Wright | Jaguar Animal Health | 61 | |
| Linda OKeefe | Acasti Pharma | N/A | |
Management Performance
| Return On Equity | -20.99 | |||
| Return On Asset | -0.26 |
Novan Inc Leadership Team
Elected by the shareholders, the Novan's board of directors comprises two types of representatives: Novan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novan. The board's role is to monitor Novan's management team and ensure that shareholders' interests are well served. Novan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Palmour, Independent Director | ||
| Paula MPH, CEO Pres | ||
| Paula Stafford, Chief Development Officer | ||
| Robert Ingram, Independent Chairman of the Board | ||
| Carri Geer, Senior Vice President and CTO | ||
| JD BS, VP RD | ||
| Machelle Sanders, Director | ||
| Richard Peterson, CFO | ||
| Stanley Hollenbach, Senior Vice President - Research and Development | ||
| Geer, Independent Director | ||
| John Gay, Principal Financial Officer, Secretary | ||
| Andrew Novak, Vice President Chief Accounting Officer and Principal Accounting Officer | ||
| MBA MD, Chief Officer | ||
| Robert Keegan, Independent Director | ||
| William Hodges, Interim CFO, Princiapl Financial Officer, Principal Accounting Officer | ||
| Sean Murphy, Independent Director | ||
| Kelly Martin, Independent Director | ||
| Nathan Stasko, President CEO, Director | ||
| Jeff Hunter, Vice President - Technical Operations | ||
| Cole Ikkala, Communications Relations | ||
| John Donofrio, COO VP | ||
| Eugene Sun, Director | ||
| Joyce Rico, Chief Medical Officer | ||
| Elizabeth Messersmith, Chief Development Officer | ||
| G Martin, Interim CEO, Director | ||
| Brian Johnson, Chief Commercial Officer | ||
| John CPA, CFO Sec |
Novan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.99 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.59) % | |||
| Current Valuation | 27.74 M | |||
| Shares Outstanding | 28.02 M | |||
| Shares Owned By Insiders | 0.86 % | |||
| Shares Owned By Institutions | 14.93 % | |||
| Number Of Shares Shorted | 462.95 K | |||
| Price To Earning | (1.49) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novan in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novan's short interest history, or implied volatility extrapolated from Novan options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Novan Stock
If you are still planning to invest in Novan Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Novan's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |